Share

    


Home / Search Results

Search Results

You searched for:

In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
In response to the increasing complexity of oncolytic agents, the associated economic burden on the patient and health system, and the intricacies associated with alternative payment models (APMs), I suggest the need for widespread establishment of chemotherapy stewardship services.